# Diabetes Research Hub — Automated Iteration Report

**Date:** 2026-06-16 (Tuesday)
**Run type:** Scheduled autonomous iteration
**State:** 285 papers tracked · 57 paths · 15 gaps · 21 queue items · 63 runs logged

## What was done this run

### 1. State load
Loaded `agent_state.json`. All 285 papers already VETTED (272 VETTED / 13 FLAGGED as legitimately off-topic). No vetting backlog. Today is Tuesday, so the weekly new-paper sweep (Mondays only) was skipped.

### 2. Credibility sweep — CLEAN
- No fabricated PMIDs in any `.py` script.
- Highest data-file PMIDs spot-verified as **real** via NCBI esummary: `42300402` (Food & Function, 8 Jun 2026) and `42299543` (Medicine (Baltimore), 12 Jun 2026). The >42M ceiling heuristic remains deprecated per doctrine notes — these are legitimate June 2026 publications.
- The `curative`/`cures` grep hits are inside `verify_before_deploy.py`'s own forbidden-term **regex/comments**, not claims.
- No "zero SAEs", "zero rejection", or overstated-preclinical language found.

### 3. Path validation — 3 paths revisited
| Path | Status | Preclinical | Clinical | Note |
|---|---|---|---|---|
| `verapamil_T1D` | PARTIALLY_VALIDATED | HIGH | **LOW-MIXED (downgraded)** | Ver-A-T1D RCT (136 pts, EASD 2025, Pieber) **missed** primary 2h-MMTT C-peptide AUC at 3/6/9/12 mo; only non-significant trends. Prior US adult RCT (Ovalle/Shalev 2018) was positive → clinical evidence now **mixed**. Ca²⁺/TXNIP mechanism unchanged. |
| `TXNIP_NLRP3_beta_cell_DKD` | PARTIALLY_VALIDATED | HIGH | NONE | Strong cross-tissue mechanistic convergence (β-cell pyroptosis + renal mesangial/podocyte DKD); all preclinical, no human RCT/meta-analysis. |
| `Treg_expansion -> T1D` (low-dose IL-2) | PARTIALLY_VALIDATED | HIGH | LOW | Treg expansion + safety robustly shown in humans; efficacy trials not powered for clinical endpoints. |

**Key signal for the human reviewer:** the verapamil → T1D story is weaker than the hub previously implied. The largest European RCT to date is a negative primary. Mechanism is sound; clinical translation is now genuinely uncertain pending the Ver-A-T1D full journal publication and the pediatric trial (NCT07199946).

### 4. Pipeline rebuild
`run_quality_improvements.py` data products regenerated:
- **PMID verification: 259/259 verified, 0 not found, 0 API errors.**
- Citation validation: 63 CONFIRMED · 57 PLAUSIBLE · 130 WEAK · 8 MISMATCH · 1 NO_DATA.
- Evidence network: 249 papers · 162 citation links · 30 topic clusters (13 FLAGGED PMIDs excluded).
- The final mismatch pretty-printer stalled on a network call (read-only, non-blocking — all output JSONs were already written). 8 mismatches remain flagged for future review.

### 5. State updated
Run appended to `run_history` (now 63 runs). Path-validation queue item advanced with `last_done = 2026-06-16` and remaining targets (vitamin_d→autoimmune, rapamycin→inflammation, tacrolimus→inflammation, rituximab→beta_cell).

## Blocker requiring user action (unchanged, priority 1)
git commit/push cannot run from the sandbox: OneDrive-synced `.git/index.lock` / `.git/HEAD.lock` are not removable here, and there is no GitHub auth in the sandbox. The branch is ~37+ commits ahead of origin/main. **From local PowerShell at `C:\Users\justi\OneDrive\Diabetes_Research`:**
```powershell
Remove-Item .git\HEAD.lock -ErrorAction SilentlyContinue
Remove-Item .git\index.lock -ErrorAction SilentlyContinue
git add -A
git commit -m "Daily iteration 2026-06-16: 3 path validations (verapamil downgraded on Ver-A-T1D null primary), credibility sweep clean, pipeline rebuild 259/259 PMIDs"
git push
```

## Next run should pick up
- Remaining PARTIALLY_VALIDATED paths (above).
- Gap #11 monthly audit due ~2026-06-27; Gap #1 (LADA gene therapy) due 2026-06-29.
- Abata ABA-201 TCR-Treg T1D readout watch (≈2026-07-02).
- Review the 8 citation mismatches flagged by the evidence-network builder.
